CDK9 inhibition as a potential therapeutic strategy in Ewing sarcoma (AACR 2023) - Mar 14, 2023 - Abstract #5984 / 13; Pres time: Apr 19, 2023; 09:00 AM - 12:30 PM; Location: Section 9; Poster Board #13; P1 | "Alvocidib demonstrated an additive inhibitory response in combination with topotecan, phosphoramide mustard, a biologically active metabolite of cyclophosphamide, and palifosfamide, a biologically active metabolite of ifosfamide, in EWS cell lines after 3-day treatment. TP-1287 may be a potential therapeutic option for the current regimen in EWS. TP-1287 is being investigated for solid tumors including EWS (clinicaltrials.gov, NCT03604783)."
Ewing Sarcoma • Hematological Malignancies • Leukemia • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • EWSR1 • FLI1 • MCL1 • MYC • RAD51
|
|
Yuta Matsumura; Richard E. Heinz; Curtis A. Allred; Adam Siddiqui; Jason M. Foulks; Steven L. Warner
|